Translate Bio (TBIO) Posts Earnings Results, Misses Expectations By $3.64 EPS

Translate Bio (NASDAQ:TBIO) announced its quarterly earnings results on Thursday. The company reported ($2.94) EPS for the quarter, missing the Zacks’ consensus estimate of $0.70 by ($3.64), Fidelity Earnings reports.

Shares of Translate Bio stock traded up $0.24 during midday trading on Friday, reaching $10.45. The company had a trading volume of 11,900 shares, compared to its average volume of 89,443. Translate Bio has a fifty-two week low of $9.21 and a fifty-two week high of $16.60.

In related news, Director Brian M. Jr. Gallagher acquired 269,230 shares of the business’s stock in a transaction that occurred on Monday, July 2nd. The shares were bought at an average cost of $13.00 per share, with a total value of $3,499,990.00. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, major shareholder Mrl Ventures Fund Llc acquired 25,000 shares of the business’s stock in a transaction that occurred on Monday, July 2nd. The stock was bought at an average cost of $13.00 per share, for a total transaction of $325,000.00. The disclosure for this purchase can be found here. 1.90% of the stock is owned by insiders.

A number of analysts have recently commented on the company. Leerink Swann began coverage on Translate Bio in a research note on Monday, July 23rd. They set an “outperform” rating and a $24.00 price target on the stock. Evercore ISI began coverage on Translate Bio in a research note on Monday, July 23rd. They issued an “outperform” rating and a $25.00 price objective on the stock. Finally, Citigroup began coverage on Translate Bio in a research note on Monday, July 23rd. They issued a “buy” rating and a $20.00 price objective on the stock.

Translate Bio Company Profile

Translate Bio, Inc, a messenger RNA therapeutics company, engages in developing medicines to treat diseases caused by protein or gene dysfunction. It is developing MRT5005 that is in Phase I/II clinical trial for the treatment of cystic fibrosis; and MRT5201 for the treatment of ornithine transcarbamylase deficiency.

Recommended Story: What does earnings per share mean?

Receive News & Ratings for Translate Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Translate Bio and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply